UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)     September 21, 2006    

PRESSURE BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS
(State or Other Jurisdiction of Incorporation)

0-21615
  
04-2652826
(Commission File Number)
  
(I.R.S. Employer Identification No.)
     
321 Manley Street, West Bridgewater, MA
  
02379
(Address of Principal Executive Offices)
  
(Zip Code)

(508) 580-1818
 (Registrant’s Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

Item 8.01  Other Events

On September 25, 2006, Pressure BioSciences, Inc. (the “Company”) announced that its Board of Directors has authorized the Company to repurchase up to $500,000 of its outstanding common stock on the open market or in privately negotiated transactions. The timing and amount of share repurchases, if any, will depend on a number of factors, including market and business conditions. The repurchases may be commenced or suspended at any time without prior notice and without further announcement. The Company also announced that pursuant to this authorization it purchased 106,600 shares of its common stock at $2.88 per share from Kyowa Medex Company Ltd., the Japanese distributor of the Company's legacy business Boston Biomedica, Inc. 
 

 
2

Item 9.01   Financial Statements and Exhibits

(d) Exhibits
 
Exhibit Number
Exhibit Description
99.1
Press Release dated September 25, 2006

 
3

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 25, 2006
PRESSURE BIOSCIENCES, INC.
     
     
     
 
By:
/s/ Richard T. Schumacher
   
Richard T. Schumacher, President and
Chief Executive Officer
 
 
 
4

 

EXHIBIT INDEX


Exhibit Number
Exhibit Description
99.1
Press Release dated September 25, 2006




5